Lilly to partner for development of Alzheimer’s treatment

September 16, 2014 3:12 PM

3 0

Lilly to partner for development of Alzheimer’s treatment

INDIANAPOLIS (Sept. 16, 2014) – Eli Lilly and Company is partnering with AstraZeneca to develop and sell a new treatment for Alzheimer’s disease.

The treatment, AZD3293, is an oral beta secretase cleaving enzyme (BACE) inhibitor that could potentially treat the disease, a fatal illness affecting an estimated five million Americans over the age of 65.

Read more

To category page

Loading...